Activation of cultured human endothelial cells (HEC) by inflammatory stimuli, such as interleukin 1 (IL-1), tumor necrosis factor (TNF), and bacterial endotoxin (lipopolysaccharide, LPS), increases their surface adhesiveness for blood leukocytes and related cell lines. We now report that activated HEC also generate a soluble leukocyte adhesion inhibitor (LAI), which accumulates in conditioned media from IL-1-, TNF-, or LPS-treated, but not sham-treated, HEC cultures. LAI significantly inhibits the adhesion of PMN and monocytes to activated, but not unactivated, HEC. In contrast, LAI has no effect on the adhesion of lymphocytes, the promyelocytic cell line HL-60 or the monocyte-like cell line U937 to HEC monolayers. LAI appears to act directly on the leukocyte, but does not inhibit either agonist-induced responses in PMN (membrane depolarization, changes in cytosolic calcium concentration, superoxide production) or PMN attachment to serumcoated plastic surfaces. Endothelial generation of LAI is blocked by actinomycin D but not by aspirin or indomethacin. Preliminary biochemical characterization indicates that LAI is a soluble, protein-containing molecule that is heat-and acidstable. Fractionation by HPLC gel filtration yields a single peak of LAI activity (14,000 < Mr > 24,000). Thus, in addition to proadhesive cell surface changes, the endothelium may also actively contribute to the regulation of endothelial-leukocyte interactions at sites of inflammation in vivo through the production of soluble adhesion inhibitors such as LAI.
Introduction
Recent studies by our laboratory and others have demonstrated that certain inflammatory cytokines, such as interleukin 1 (IL-1), tumor necrosis factor (TNF),' as well as gram Receivedfor publication 12 June 1987 and in revisedform 18 April 1988.
1. Abbreviations used in this paper: CM, conditioned media; ELAM-1, endothelial-leukocyte adhesion molecule-1; GM-CSF, granulocyte-monocyte colony stimulating factor; HEC, human umbilical vein endothelial cell(s); hmIL-1, human monocyte-derived interleukin 1; LAI, leukocyte adhesion inhibitor; LPS, gram negative bacterial endotoxin; rIL-1 (a, 13), recombinant IL-1; rTNF, recombinant tumor necrosis factor; TIS, transferrin/insulin/selenium. negative bacterial endotoxin (lipopolysaccharide, LPS), can act directly on cultured human endothelial cells to increase the adhesiveness of their surfaces for human blood leukocytes and the related leukocyte cell lines HL-60 and U937 (1) (2) (3) (4) (5) (6) (7) (8) . Further, we have shown that this increased endothelial adhesiveness for PMN and HL-60 cells can be attributed, in part, to expression of a newly synthesized cell surface structure we have designated endothelial-leukocyte adhesion molecule-i (ELAM-l) (9) .
While investigating the potential contributions of soluble products released by the cytokine-activated endothelial cell to this adhesive interaction, we became aware of a potent inhibitor of leukocyte adhesion. We now report that cultured human endothelial cells treated with IL-l, TNF, or LPS, produce a soluble, noncyclooxygenase-dependent inhibitor that acts selectively on PMN and monocytes, but not lymphocytes, to block their adhesion to the "hyperadhesive" endothelial surface. The action ofthis endothelial-derived leukocyte adhesion inhibitor (LAI) appears to be directed towards the leukocyte; however, it does not produce a global inhibition of leukocyte responsiveness to soluble inflammatory stimuli, such as the chemotactic peptide, FMLP, leukotriene B4 (LTB4), and phorbol 12-myristate 13-acetate (PMA). LAI may play a role in the modulation of leukocyte-vessel wall interactions at sites of inflammation in vivo.
Methods
Cell cultures. Human umbilical vein endothelial cells were isolated from two to five cord segments, pooled and grown in primary culture using medium 199 (M199; M.A. Bioproducts, Bethesda, MD) with 20% fetal calfserum (FCS; Gibco Laboratories, Grand Island, NY) and antibiotics as previously described (1) . Several strains were serially passaged (1:3 split ratios) using M199-20% FCS supplemented with endothelial cell growth factor (50-100 ,g/ml; Biomedical Technologies, Inc., Stoughton, MA) and porcine intestinal heparin (50-100 ,gg/ml; Sigma Chemical Co., St (9) . The efficacy of treatment with the cyclooxygenase inhibitors was determined by radioimmunoassay of 6-keto-PGF,,, production in cytokine-activated and unactivated HEC with and without addition of calcium ionophore (courtesy ofDr. A. Schafer, Brigham and Womens' Hospital, Boston, MA).
Assay ofLAI activity. LAI activity was assayed using a modification of our previously described leukocyte-endothelial monolayer adhesion assay (9) . In brief, target monolayers, consisting of confluent HEC grown on Thermanox coverslips or in microtiter wells, were pretreated in RPMI supplemented with FCS, BSA, or TIS with and without hmIL-l or rIL-j I (2.5-5 U/ml, 4 h). Aliquots of "'In-labeled leukocyte suspensions (2 X 107 cells/ml in RPMI with the appropriate supplement) were diluted 1:10 in IL-l CM, SHAM CM, or fresh medium (final concentration: 2 X 106 cells/ml), added to washed monolayers, and incubated at 370C for 10 min under static conditions. The adhesion assay was terminated by a standardized wash procedure for Thermanox coverslips (1), or by centrifugation (350 g, 5 min) in the case of microtiter plates (9, 1 1). The number of adherent "' In-labeled leukocytes was determined from the monolayer bound radioactivity and the specific activity (counts per minute per cell) of the leukocyte preparation using a gamma 5500 counter (Beckman Instruments, Inc., Fullerton, CA). LAI To test adhesion to serum-coated plastic surfaces, 50 Ml of 50% fresh human serum, 50% decomplemented (560C, 30 min) human serum, or 50% zymosan activated human serum was added to microtiter plates and incubated at 370C for 1-2 h. The wells were washed with HBSS minus immediately before the addition of radiolabeled PMN and further incubated for 30 min at 370C. The number of adherent leukocytes per square millimeter of plastic surface was determined as described above.
Assays ofPMN activation. PMN responsiveness to soluble stimuli (10-7 M FMLP, l0-7 M LTB4, 100 ng/ml PMA) was assessed by quantitative measurement of changes in membrane potential and cytosolic free calcium concentrations. Changes in membrane potential were evaluated with the fluorescent cyanine probe diS-C3-(5) as previously described (12, 13) using a SPEX (Edison, NJ) Fluorolog II (model CM-1) spectrofluorimeter with the cuvette compartment controlled at 370C and equipped for continuous stirring of cell suspensions. For measurement of Ca2+-sensitive Fura-2 fluorescence, suspensions of PMN (107 cells/ml) were resuspended in HBSS without Ca2" and Mg2+ and incubated with Fura-2/AM (stock solution, 1 mM in dimethylsulfoxide), at a final concentration of 1 MM, for 10 min at 370C. The cells were diluted 5-fold with HBSS with 0.5% BSA and further incubated for 15 min at 37°C. The cells were washed twice by centrifugation with cold HBSS with 0.1% BSA and stored at 10°C. Immediately before assay, cells were pelleted in a Beckman Microfuge (model B), resuspended in 1.9 ml of warm HBSS plus Ca2+ and Mg2+, and allowed to equilibrate in a cuvette for 5 min before addition of agonists. Fluorescence measurements were made in a SPEX Fluorolog II spectrofluorimeter equipped with a beam splitter, two excitation monochromaters, and a dual mirror chopping mechanism in a specialized optical configuration to allow rapid alternating (30 Hz) excitation of Fura-2 at two wavelengths, 340 and 380 nm. Excitation band widths were set at 6.6 nm. The ratio of the emitted fluorescence signals (505 nm, 7.2 nm) permits the calculation of intracellular Ca2" concentration, which is independent of cell number, dye loading, and dye bleaching. Fluorescence signals were calibrated using 80 MM digitonin to permit equilibration of intracellular and extracellular Ca2" (fluorescence maximum) followed by the addition of 100 mM Tris, 300 mM EGTA, pH > 10.0 (fluorescence minimum). The basal and maximum increase in intracellular Ca2+ were calculated as described by Grynkiewicz et al. (14) . Superoxide generation was determined using cytochrome c reduction assay as described by Cohen et al. (15) .
Enzymatic treatments ofLA!. SHAM CM and IL-l CM collected in RPMI plus TIS were filtered through an Amicon YM 30 membrane (nominal molecular weight cut-off 30,000; Amicon Corp., Danvers, MA) under N2 and treated with trypsin (1000 U/ml, pH 7, 37°C, 18 h), thrombin (2 U/ml, 37°C, 2 h), heparinase (15 U/ml, 30°C, 2 h), or pepsin-linked agarose (4,500 U/ml, pH 4, 18 h, 37°C). Enzyme treatments were stopped by boiling (15 min, 100°C) or, in the case of pepsin-linked agarose, by centrifugation in a Beckman microfuge and removal of the agarose beads. Trypsin and thrombin retained full activity in both SHAM CM and IL-I CM as determined by the hydrolysis of BAEE (N a-benzoyl-L-arginine ethyl ester; Sigma Chemical Co.) in a spectrophotometric assay and plasma clotting activity, respectively.
HPLC. HPLC was performed with a Waters Associates (Milford, MA) liquid chromatography system composed of two model 510 solvent pumps and a programmable Systems Controller gradient maker. Column effluent was monitored at 280 nm with a Waters model 481 absorbance detector. IL-I CM and SHAM CM in RPMI plus TIS were filtered on an Amicon YM 30 membrane, the effluent concentrated 20-40 times on a YM 5 membrane (nominal molecular weight cut-off 5,000), dialyzed against distilled H20 (Spectrapor 7, 10,000 molecular weight cutoff, Spectrum Medical Industries, Los Angeles, CA), and lyophilized. Lyophilized samples were reconstituted in 0.2 M acetic acid, 0.1 M triethylamine (pH 3.9) at a concentration of -1 mg/ml and applied (250-Ml sample) to a Waters Protein-PAK 125 gel filtration column (7.8 mm X 30 cm). The column was run as an isochratic system at a flow rate of 1.8 ml/min and 0.9-ml fractions were collected. Fractions were dialyzed 18 h (40C) against PBS (136 mM NaCi, 0.3 mM KCI, 0.8 mM Na2HPO4, 0.1 mM KH2PO4, pH 7.4). Fractions were diluted into RPMI plus FCS and assayed in a standard monolayer adhesion assay. Protein determinations were performed using Bio-Rad protein reagent (Bio-Rad Laboratories, Richmond, CA).
Results
As illustrated in Fig. 1 , treatment of HEC monolayers with hmIL-1 results in a time-dependent increase in surface adhesiveness for polymorphonuclear leukocytes, as we have previously reported (1). In our standard monolayer adhesion assays, the cytokine-containing medium routinely was aspirated and each well washed with fresh medium immediately before the addition of radiolabeled leukocytes. In this "washed" system, PMN adhesion to IL-I treated HEC monolayers was significantly increased with respect to untreated monolayers as early as 1 h post-IL-1, with peak adhesion occurring between 3 and 4 h, followed by a gradual decline. In contrast, when the pretreatment media was not removed and PMN were added directly to the well (unwashed system), markedly less PMN adhesion was observed especially after 3 h. PMN adhesion to untreated HEC monolayers was the same for both washed and unwashed conditions at all time points examined. Based on these observations, we hypothesized that the conditioned media from IL-l-treated, but not untreated, HEC monolayers contained an activity that inhibits leukocyte-endothelial adhesion (LAI).
To test this hypothesis, conditioned media were collected from endothelial cell cultures grown in 100-mm dishes. The HEC were washed to remove culture media and incubated in RPMI plus FCS with and without IL-I for 4 h, at which point the HEC were washed again. After were collected and assayed for inhibition of PMN adhesion to treated and untreated HEC monolayers. PMN adhesion to untreated HEC monolayers was unaltered by the presence of IL-I CM as compared to SHAM CM (10±4% inhibition, 10 experiments, P > 0.05). In contrast, PMN adhesion to hyperadhesive HEC monolayers (pretreated with 2.5-5 U/ml rIL-l, 4 h) was significantly inhibited in the presence of IL-I CM (72±6% inhibition, 10 experiments, P < 0.001), as compared with SHAM CM. As illustrated in Fig. 2 , when the extent of PMN adhesion to untreated or cytokine-treated HEC monolayers in the presence of SHAM CM was compared to fresh buffer, no significant difference was observed. Furthermore, SHAM CM, to which rIL-I, (5 U/ml) was added just before assay, had no effect on PMN adhesion to either treated or untreated HEC monolayers. Incubation of rIL-l,3 (5 U/ml)-containing medium in the absence of endothelial cells (Cellfree CM) did not result in the generation of inhibitory activity.
In addition to human monocyte-derived IL-1 and human recombinant IL-1 B, certain other agents including human recombinant IL-la, human recombinant TNF and bacterial LPS, also induced the generation of LAI activity by HEC monolayers ( Generation of LAI activity was found to be IL-I concentration dependent with threshold at 0.1 U/ml rIL-lI and maximal stimulation at 2.5-5 U/mi (Fig. 3) . The appearance of LAI activity in the IL-I CM was time dependent, as seen in fractionated hourly collections, with inhibitory activity consistently detectable at 1-2 h (30±6%, five experiments), reaching a maximum at 5-6 h (65±2%, five experiments) following exposure to IL-1. LAI activity passed freely through an Amicon YM 30 (nominal molecular weight cutoff: 30,000) but was concentrated 10-20 times on an Amicon YM 5 (nominal molecular weight cutoff: 5,000). PMN adhesion was maximally blocked at a 5X concentration of IL-i CM (75±7%, five expenments) with proportionately less LAI activity detectable at lower IL-1 CM concentrations (Fig. 4) . To determine whether LAI exerts its inhibitory effect on the leukocyte or the endothelial cell, each cell type was selectively pretreated. When activated HEC monolayers (5 U/ml rIL-Ifl, 4 h) were incubated for 30 min with IL-I CM, followed by exchange with fresh medium (1.5 ml), no inhibition of PMN adhesion was observed (5±8% inhibition, P > 0.05, three experiments). In contrast, when PMN (3 X 107 cells in 1.5 ml) were pretreated with IL-I CM for 30 min, centrifuged (100 g, 2 min), resuspended in a comparable volume of fresh medium and added to an activated HEC monolayer, PMN adhesion was significantly inhibited (25±3% inhibition, P < 0.001, three experiments). In addition, adhesion of unfixed PMN to fixed IL-1-stimulated HEC monolayers (2% paraformaldehyde in PBS, 5 min, 220C, then stored overnight in PBS plus BSA at 40C) continued to be significantly inhibited by IL-l CM (45±9% inhibition, two experiments). In contrast, brief fixation of the PMN (2% paraformaldehyde in PBS, 5 min, on ice) reduced the inhibitory effect of LAI by > 80%. PMN fixation, per se, did not alter adhesion to untreated or IL-1-treated HEC monolayers (data not shown). These observations suggest that the inhibitory action of LAI is primarily directed at the leukocyte. Conditioned medium from IL-I-stimulated HEC produced comparable inhibition of PMN adhesion to HEC target monolayers activated with TNF (200 U/ml, 4 h; 54±4%, five experiments), LPS (1 ug/ml, 4 h; 56±7%, three experiments), or IL-I# (2.5 U/ml, 4 h; 68±4, five experiments). In contrast, IL-i CM did not inhibit PMN adhesion to plastic surfaces coated with fresh human serum (4±3% inhibition, four experiments), decomplemented human serum (-10±4%, three experiments) or zymosan activated human serum (-8±10%, three experiments). These results, taken together with the lack of effect on PMN adhesion to unactivated endothelial cells, suggest that LAI may act to preferentially inhibit leukocyte interaction with the "hyperadhesive" endothelial cell surface.
As illustrated in Fig. 5 , LAI activity appears to differentially affect the adhesion of certain blood leukocytes to cytokine-activated and unactivated endothelium. IL-i CM consistently produced a marked inhibition of PMN adhesion to activated HEC monolayers (76±4% inhibition of cytokinestimulated adhesion, P < 0.001, five experiments), but had no effect on PMN adhesion to unactivated monolayers. Similarly, monocyte adhesion to activated HEC monolayers was significantly inhibited (55±12% inhibition of cytokine-stimulated adhesion, P < 0.01, five experiments), while no effect on the relatively extensive adhesion to unactivated monolayers was observed. In contrast, IL-I CM did not significantly alter the adhesion of peripheral blood lymphocytes (-4±6% inhibition, P > 0.1, three experiments), HL-60 cells (2±6%, P > 0.1, four experiments), or U937 (1±9%, P > 0.1, four experiments) to either IL-I-activated or unactivated HEC monolayers.
Vital microscopy of PMN adhesion to activated HEC monolayers in the presence and absence of LAI revealed striking differences. In SHAM CM, large numbers of adherent PMN appeared well spread on the monolayer surface (Fig. 6  A) . In contrast, in IL-I CM, the extent of PMN adhesion was markedly reduced, consistent with the quantitative monolayer adhesion assay data. Interestingly, although individual PMN had undergone shape change with pseudopod extension, they did not appear spread on the monolayer surface in the presence of IL-I CM (Fig. 6 B) . To determine whether LAI was producing a global inhibition of leukocyte function, we examined stimulus-response coupling and superoxide production in response to soluble stimuli. The addition of IL-1 CM or SHAM CM did not alter resting membrane potential or inhibit membrane depolariza- (Fig. 7 A) . Similarly, neither IL-l CM nor SHAM CM altered FMLP-induced rises in cytosolic calcium levels (Fig. 7  B) . Superoxide production in response to 10-7 M FMLP or 100 ng/ml PMA also was not inhibited by LAI (data not shown). Based on these results, LAI does not appear to interfere with leukocyte activation by soluble inflammatory stimuli.
To facilitate preliminary biochemical characterization, LAI was collected from IL-1 activated HEC monolayers in serum-free, transferrin/insulin/selenium-supplemented medium. LAI activity in these preparations was found to be stable to a variety oftreatments, including boiling for 20 min, acidification (pH 2 or 4) for 18 h, freezing (-80'C, up to 3 mo) and storage at 4VC for up to 14 d without the addition of protease inhibitors. LAI activity was non-sedimentable (250,000 g, 45 min) suggesting that it is soluble rather than associated with a membrane fragment. LAI activity was precipitated by ammonium sulfate at 60-80% saturation, and full activity was recovered in this fraction. LAI activity was not adsorbed by gelatinagarose, concanavalin A-agarose, or heparin-sepharose. Treatment of IL-l CM, which had been filtered through a 30,000 molecular weight cutoff membrane, with trypsin (1,000 U/ml, pH 7, 370C, 18 h), thrombin (2 U/ml, 370C, 2 h), or heparinase (15 U/ml, 30'C, 2 h), did not affect LAI activity, whereas treatment with pepsin-linked agarose (4,500 U/ml, pH 4, 18 h, 370C) significantly reduced LAI activity (13±7% in pepsintreated samples vs. 62±8% in acid-treated control samples, two experiments). These results suggest that the biological activity of LAI depends on a protein component.
Samples of ultrafiltered, dialyzed and lyophilized IL-I CM were fractionated on a Waters Protein-Pak 125 gel filtration column by high pressure liquid chromatography as described in Methods. Fractions (0.8 ml) were dialyzed against PBS (pH 7.4), diluted 1:10 in RPMI plus FCS and assayed for LAI activity. In this chromatography system, the peak ofLAI activity (fraction 12) was separated from the major protein peak (fraction 9) (Fig. 8) . LAI activity in the peak fraction was present at an effective concentration of 80X, based on serial dilution to the endpoint of 50% inhibition of PMN adhesion. The total LAI activity recovered, as estimated from assay of serial dilutions ofeach active fraction, was > 90%. LAI activity in the peak fraction was stable to boiling, acidification, and was completely destroyed by treatment with pepsin (-8±6% LAI activity in pepsin-treated samples vs. 62±10% in acidtreated control samples), thus confirming its protein nature.
Discussion
Adhesion of leukocytes to the endothelial lining of blood vessels is an essential event in the inflammatory process. In addition to the proadhesive cell surface changes observed in the "activated" endothelial cell (1-9), cytokine-and bacterial endotoxin-stimulated endothelial cultures also generate an antiadhesive activity, specifically, an inhibitor of leukocyte adhesion (LAI). LAI is an inducible, soluble product released by the activated endothelial cell, the biological activity ofwhich is protein dependent. No detectable LAI activity is found in conditioned medium from untreated human endothelial cultures. Cytokine treatment of endothelial cultures has been reported to result in altered production of several biologically .0 100 (16, 17) . However, its protein nature, thermo-and acid stability and production in the presence of aspirin or indomethacin (at concentrations that ablate cyclooxygenase activity in cultured endothelial cells [ 18] ), distinguish LAI activity from various endogenous phospholipid metabolites that have been shown to influence leukocyte function (19) (20) (21) .
LAI significantly reduces the extent of leukocyte adhesion to activated endothelial cells without producing a global inhibition ofleukocyte function. This selective action is in contrast to that of certain other known inhibitors of leukocyte function produced by endothelial cells. For example, adenosine, which is released by cultured endothelial cells under basal conditions (22) as well as in response to oxidant stress (23), inhibits both FMLP-stimulated PMN adhesion to unactivated endothelial cells (24) and PMN superoxide production (25, 26). Other chemically undefined endothelial-derived substances also appear to inhibit PMN adhesion to unstimulated endothelial monolayers and inert (plastic) surfaces (27, 28) . Interestingly, purified human monocyte-derived IL-1 has also been reported to inhibit PMN adhesion to inert surfaces (29). However, in our assay system, the direct addition of rIL-1I3 was found to be without effect on PMN adhesion to unactivated or cytokineactivated HEC monolayers.
The leukocyte type-selective effect of LAI, that is, the inhibition of PMN and monocyte adhesion, but not lymphocyte, HL-60 or U937 adhesion, suggests that the action of LAI may be directed at functions or surface structures that vary with leukocyte type and/or are deficient in the less differentiated cell lines. Adhesive interactions of certain leukocytes with cultured endothelium, under both activated and basal conditions, have been demonstrated to involve, in part, the leukocyte surface differentiation antigen complex CDl 1/18 (LFA-1, Mac-l, p150,95) (6-8, 30, 31) . It remains to be determined if LAI interacts with components of the CDl 1/18 complex to produce its inhibitory effect. Interestingly, concentrated LAI (up to five times) did not inhibit either the adhesion of PMN stimulated with FMLP, LTB4 or PMA to unactivated endothelial monolayers (Wheeler, M. E., unpublished observations), or the adhesion of unstimulated PMN to serum-coated inert surfaces. In contrast, monoclonal antibodies to CD 1 I/ 18 complex produce a significant inhibition of agonist-induced PMN adhesion to unactivated endothelial monolayers as well as to inert surfaces (32) . These results suggest that LAI may interfere with PMN adhesion mechanisms uniquely involved in the recognition of the activated endothelial cell surface.
Studies from our laboratory have implicated the inducible expression of endothelial-leukocyte adhesion molecules (ELAMs) in the cytokine-stimulated "hyperadhesive" surface change (1-3, 9, 33) . Specifically, ELAM-1 has been shown to be involved in PMN and HL-60 adhesion to IL-l treated endothelium and monoclonal antibodies against ELAM-l (H4/18 and HI 8/7) block this adhesion (9) . These observations raise the question of a potential relationship between ELAM-1 and LAI. For example, it is possible that LAI may be a "shed" portion ofthe ELAM-I molecule that can compete with endothelial cell surface-expressed ELAM-1 for its putative PMN receptor. However, under conditions where monoclonal antibodies H4/18 and H18/7 immunoprecipitate ELAM-1 from detergent cell extracts (9, 33), LAI activity was not removed from IL-1 CM. In addition, when LAI and H18/7 were both present in the adhesion assay, PMN adhesion to activated endothelial cells was inhibited in an additive fashion, thus suggesting that LAI does not act by blocking the putative PMN receptor for ELAM-1 (Wheeler, M. E., unpublished observations).
In summary, we have demonstrated that cultured human endothelial cells, stimulated by cytokines or endotoxin, not only express surface molecules that enhance leukocyte adhesion, but also generate a soluble, protein-containing inhibitor that selectively inhibits leukocyte attachment to the hyperadhesive endothelial surface. In combination, these active endothelial pro-and antiadhesive alterations may be part ofa physiologic mechanism that regulates local leukocyte-vessel wall adhesive interactions at sites of inflammation in vivo. Further characterization of LAI may provide insight into "natural" antiinflammatory mechanisms.
